Biopharmaceutical Analysis eBook
Read the article:
Improving IR Spectroscopy as a Tool for Biopharmaceutical Analysis
Read the ebook:
BioPharm International’s Biopharmaceutical Analysis eBook
|Articles|August 2, 2021
- Pharmaceutical Technology's In the Lab eNewsletter, August 2021
- Volume 16
- Issue 08
Improving IR Spectroscopy as a Tool for Biopharmaceutical Analysis
Author(s)Holly Lombardo, Matthew McGann
A recent innovation in infrared spectroscopy, Microfluidic Modulation Spectroscopy has been shown to improve characterization of secondary protein structure.
Advertisement
Over the past two decades, the biopharmaceutical industry, along with the associated regulatory authorities and analytical instrument suppliers, have progressed toward clearer identification of the attributes that are critical for ensuring the quality of biopharmaceuticals and how to measure them efficiently.
The need to understand and predict these molecules’ behavior drives a requirement for new informational insights. This article puts the spotlight on infrared spectroscopy and recent innovations, including the introduction of Microfluidic Modulation Spectroscopy.
About the authors
Holly Lombardo*, HLombardo@redshiftbio.com, is product manager, and Matthew McGann is marketing manager; both are at RedShiftBio.
*To whom all correspondence should be addressed.
Articles in this issue
over 5 years ago
Preparing for Unexpected Issues in E&L Studies for Biopharmaover 5 years ago
Thermo Fisher Expands Hematology Oncology NGS Portfolioover 5 years ago
Summa Equity Acquires Majority Stake in Axion BioSystemsover 5 years ago
Artificial Intelligence Facilitates Empty Well Detectionover 5 years ago
J.T.Baker Robotic Tips from Avantor Offer Precision WorkflowAdvertisement
Related to this article
Impurity deficiencies in submissions are remarkably consistent. Subathra Ramamoorthy, Veranova, explains how to catch them before agency filing.
Subathra Ramamoorthy, Veranova, on how forced degradation and trace impurity profiling in potent APIs shape regulator-ready analytical methods.
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why Impurity Deficiencies Keep Repeating: AAPS PharmSci 360 2026
2
Drapeau’s AI Deep Dive: The Price of Acceptance in Regulated AI
3
Why Drug Shortages Average 5+ Years: PharmTech Explained
4
Expert Commentary on Formulation, Scale-Up, and Patient-Centered Design Found at CPHI Milan
5